Cognitive, behavioral and metabolic effects of oral galactose treatment in the transgenic Tg2576 mice

Babic Perhoc, Ana; Osmanovic Barilar, Jelena; Knezovic, Ana; Farkas, Vladimir; Bagaric, Robert; Svarc, Alfred; Grünblatt, Edna; Riederer, Peter; Salkovic-Petrisic, Melita

doi:10.1016/j.neuropharm.2018.12.018

Citations

Citation copied

Babic Perhoc, A., Osmanovic Barilar, J., Knezovic, A., Farkas, V., Bagaric, R., Svarc, A., Grünblatt, E., Riederer, P., & Salkovic-Petrisic, M. (2019). Cognitive, behavioral and metabolic effects of oral galactose treatment in the transgenic Tg2576 mice. Neuropharmacology, 148, 50–67. https://doi.org/10.1016/j.neuropharm.2018.12.018

Abstract

Alzheimer's disease (AD) is the most common neurodegenerative disorder associated with insulin resistance and glucose hypometabolism in the brain. Oral administration of galactose, a nutrient that provides an alternative source of energy, prevents and ameliorates early cognitive impairment in a streptozotocin-induced model (STZ-icv) of the sporadic AD (sAD). Here we explored the influence of 2-month oral galactose treatment (200 mg/kg/day) in the familial AD (fAD) by using 5- (5M) and 10- (10M) month-old transgenic Tg2576 mice mimicki